Abstract：Objective: To explore the effects of compound anisodine on serum malondialdehyde (MDA) and superoxide dismutase (SOD) levels in patients with acquiredparalytic strabismus. Methods: A total of 100 patients with acquiredparalytic strabismus from April 2017 to August 2018 in the hospital were selected and randomly divided into observation group and control group, with 50 cases in each group. Control group was given routine treatment, and observation group was given compound anisodine on the basis of control group. The clinical efficacy, MDA and SOD levels, hemodynamic indexes and occurrence of adverse reactions were compared between the two groups. Results: The effective rate of clinical treatment in observation group was higher than that in control group (96.00% vs 80.00%) (P<0.05). The non-diplopia area after treatment in observation group was higher than that in control group, and the prism strabismus was lower than that in control group (P<0.05). The SOD level after treatment in observation group was higher than that in control group while the MDA level was lower than that in control group (P<0.05). The whole blood viscosity, plasma viscosity, erythrocyte aggregation index and hematocrit value in observation group were lower than those in control group (P<0.05). There were no obvious adverse reactions during treatment in the two groups. Conclusions: Compound anisodine can increase the area without diplopia, reduce the degree of prism strabismus, decrease the content of MDA in serum, increase the level of SOD and improve the index of hemorheology.
2019, Vol. 25 
冀公网安备13080202000677号